We spoke to BBG Advanced Therapies COO Adrienne Mendoza to learn how one company is tackling the challenges of cell therapies.

Viridian and Kissei Pharmaceutical have signed an exclusive partnership and license agreement for advancing veligrotug and VRDN-003.

Director-general for WHO says leaders want self-reliance, with tobacco and alcohol tax rises on the cards to boost domestic revenue.

The Maryland Prescription Drug Affordability Board (PDAB) found that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) present affordability ...

Analysts say the departure of the CBER head may alleviate overhang in the cell and gene therapy space. Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and ...